RESULTS OF PONATINIB AS FRONTLINE THERAPY FOR CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE

EHA Library, Fadi Haddad, 420782

LOWER-DOSE INITIATING BOSUTINIB IS SAFE AND EFFECTIVE FOR RESISTANT OR INTOLERANT TO PRIOR THERAPY CHRONIC MYELOID LEUKEMIA PATIENTS (BOGI TRIAL): A SINGLE-ARM, MULTICENTER, PHASE II TRIAL

EHA Library, Shinya Kimura, 420783

ASC4REAL: EFFICACY AND TOLERABILITY COMPARISON BETWEEN ASCEMBL STUDY, A PHASE 3 RANDOMIZED CLINICAL TRIAL (RCT), AND REAL-WORLD (RW) EXPERIENCE WITH ASCIMINIB IN CML PATIENTS BEYOND 2 TKIS

EHA Library, Anchit Khanna, 420784

CLINICAL EFFICACY OF FIRST-LINE NILOTINIB OR IMATINIB THERAPY IN PATIENTS WITH CHRONIC MYELOID LEUKAEMIA – NATIONWIDE REAL LIFE DATA

EHA Library, Daniela Zackova, 420785

OLVEREMBATINIB OVERCOMES PONATINIB AND ASCIMINIB RESISTANCE IN PATIENTS (PTS) WITH HEAVILY PRETREATED CHRONIC MYELOID LEUKEMIA (CML) AND PHILADELPHIA-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (PH⁺ ALL)

EHA Library, Elias Jabbour, 420786

BCR::ABL1 KINETICS IN CHRONIC PHASE (CP) CHRONIC MYELOID LEUKEMIA (CML) PATIENTS AFTER PONATINIB VERSUS NILOTINIB TREATMENT FRONT-LINE

EHA Library, Franck Emmanuel Nicolini, 420787

TREATMENT PATTERNS AND REAL-WORLD CLINICAL OUTCOMES OF PATIENTS WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE TREATED WITH ASCIMINIB IN ONCOLOGY PRACTICES IN THE UNITED STATES

EHA Library, Ehab Atallah, 420788

PROPENSITY SCORE MATCHING ANALYSIS COMPARING ASCIMINIB VERSUS PONATINIB FOR ITS TREATMENT OUTOMES IN CHRONIC MYELOID LEUKEMIA PATIENTS

EHA Library, Maria Agustina Perusini, 420789

IL10 AND IL15 SIGNIFICANTLY PLUMMETED IN PATIENTS PRESENTING WITH TYROSINE KINASE INHIBITOR WITHDRAWAL SYNDROME (TWS). PRELIMINARY RESULTS FROM THE « KIWIS » STUDY DESIGNED FOR TWS.

EHA Library, Hyacinthe Atchroue Johnson Ansah, 420790

ANALYSIS OF FACTORS AFFECTING THE ACQUISITION OF MR4.5 UNDER FIRST-LINE IMATINIB TREATMENT

EHA Library, Jian Huang, 420792

KRAS MUTATION PREDICTS POOR OUTCOME IN PATIENTS WITH MYELOID BLAST PHASE CHRONIC MYELOID LEUKEMIA RECEIVING THIRD GENERATION TYROSINE KINASE INHIBITORS COMBINED WITH AZACITIDINE

EHA Library, Mei Bao, 420793

ASCIMINIB AS INITIAL THERAPY FOR PATIENTS WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (ALERTCML)

EHA Library, Ehab Atallah, 420794

DECIPHERING TELOMERES VARIANTS IN MYELOID NEOPLASMS: INSIGHTS INTO TERT VARIANTS OF UNCERTAIN SIGNIFICANCE.

EHA Library, Ludovica Marando, 420795

CHARACTERIZATION OF THE MOLECULAR SIGNATURE OF HUMAN MONOCYTES IN MYELODYSPLASTIC SYNDROME AND AGING.

EHA Library, Ioannis Kotsianidis, 420796

GENETIC CHARACTERIZATION OF CHIP IN CARDIOVASCULAR DISEASES IN COMPARISON TO MYELOID MALIGNANCIES

EHA Library, Manja Meggendorfer, 420797

GENOTYPE/PHENOTYPE ASSOCIATIONS IN MDS - HOW GENETICS IMPACT CYTOPENIA

EHA Library, Sandra Huber, 420798

MOLECULAR LANDSCAPE OF A MDS/MPN COHORT

EHA Library, Diana Margarita Trejos Carvajal, 420799

PATHOGENESIS OF MYELOID NEOPLASMS WITH DER(1;7)(Q10;P10)

EHA Library, Rurika Okuda, 420800

MORPHOLOGY-INSPIRED GENETIC GROUPS FOR STRATIFICATION OF MDS PATIENTS WITH INCREASED BLASTS

EHA Library, Maki Sakuma, 420801

CLASSIFICATION AND PROGNOSTIC STRATIFICATION BASED ON GENOMIC FEATURES IN MYELOID DYSPLASTIC NEOPLASMS, MYELOPROLIFERATIVE NEOPLASMS AND THEIR OVERLAPPING CONDITIONS.

EHA Library, Jong-Mi Lee, 420802

U2AF1 S34F MUTATION CAUSED DYS-MEGAKARYOPOIESIS THROUGH CHK1 ABERRANT SPLICING IN MDS

EHA Library, Wenjun Zhang, 420803

MDS-PB13 SCORE - A NEW SCREENING METHOD FOR MDS ASSOCIATED ABERRANCIES BY FLOW CYTOMETRY IN BLOOD: IMPLICATIONS FOR DIAGNOSIS AND PROGNOSIS

EHA Library, Uta Oelschlaegel, 420804

SENECTUS IPSA MORBUS EST? HOW TO DISTINGUISH INFLAMMAGING FROM INFLAMMATION OF MYELODYSPLASTIC SYNDROMES BY AN ARTIFICIAL INTELLIGENCE APPROACH.

EHA Library, elena tofacchi, 420805

SOMATIC MUTATIONS AND DNA METHYLATION IDENTIFY A SUBGROUP OF POOR PROGNOSIS WITHIN LOWER RISK MYELODYSPLASTIC SYNDROMES

EHA Library, Michaela Fontenay, 420806

PARALLEL MONITORING OF MEASURABLE RESIDUAL DISEASE AND CHIMERISM BY NGS IN MYELODYSPLASTIC SYNDROME AFTER ALLOGENIC STEM CELL TRANSPLANT

EHA Library, Irene Zamanillo, 420807

TARGETING DYSREGULATION OF IRON HOMEOSTASIS IN MDS MICE WITH AN OPTIMISED GALNAC-CONJUGATED TMPRSS6 SIRNA

EHA Library, Jim Vadolas, 420808

CD56 EXPRESSION IN MYELODYSPLASTIC SYNDROMES: REVIEWING OLD DATA WITH FRESH EYES.

EHA Library, Valerie BARDET, 420809

CLONAL HIERARCHY OF SOMATIC MUTATIONS IN MYELODYSPLASTIC NEOPLASMS

EHA Library, Claudia Haferlach, 420810

NAMPT INHIBITORS TARGET MYELOBLASTS FROM HIGH-RISK MDS PATIENTS WITH MONOSOMY 7 OR DELETION 7Q

EHA Library, Nemo Ikonen, 420811

NHEJ DNA-REPAIR PATHWAY GERMLINE VARIANTS IN EARLY-ONSET ADULT MYELODYSPLASTIC SYNDROMES: HOMOLOGOUS RECOMBINATION DEFICIENCY SCORE AND CLINICAL IMPACT

EHA Library, Maria Gabarrós-Subirà, 420812

COMPARATIVE ANALYSIS OF CLINICAL BENEFIT BY GENOMIC LANDSCAPE AND MUTATIONAL BURDEN OF LUSPATERCEPT VERSUS EPOETIN ALFA IN LOWER-RISK MYELODYSPLASTIC SYNDROMES (MDS) IN THE PHASE 3 COMMANDS STUDY

EHA Library, Rami S. Komrokji, 420813

ELTROMBOPAG RESTORES PROLIFERATIVE CAPACITY AND ADIPOSE-OSTEOGENIC BALANCE OF MESENCHYMAL STROMAL CELLS IN PATIENTS WITH LOW-RISK MYELODYSPLASTIC SYNDROMES

EHA Library, Minghua Hong, 420814

POLY(RC)-BINDING PROTEIN 1 REPRESSES FERROPTOSIS IN ANEMIA OF MYELODYSPLASTIC SYNDROMES  THROUGH THE P53/SLC7A11/ALOX12 PATHWAY

EHA Library, Mengying Zhang, 420815

CLONAL HIERARCHY OF PPM1D MUTATION IMPACTS RISK OF TRANSFORMATION TOWARDS THERAPY-RELATED MYELOID NEOPLASMS

EHA Library, David Fandrei, 420816

SINGLE CELL PROFILING OF DEL(5Q) MDS UNVEILS ITS TRANSCRIPTIONAL LANDSCAPE AND THE IMPACT OF LENALIDOMIDE

EHA Library, Nerea Berastegui Zufiaurre, 420817

DNA METHYLATION PROFILING OF MYELODYSPLASTIC SYNDROMES AND CLINICAL RESPONSE TO AZACITIDINE: A MULTICENTER RETROSPECTIVE STUDY

EHA Library, Ignacio Campillo-Marcos, 420818

IDENTIFICATION OF TRANSCRIPTIONAL ALTERATIONS LEADING TO ABERRANT MYELOID DIFFERENTIATION IN MYELODYSPLASTIC SYNDROMES

EHA Library, Aintzane Díaz-Mazkiaran, 420819

HIGH PROPORTION OF CD95+/CD45RA- REGULATORY T CELLS IN THE BONE MARROW OF MDS PATIENTS IS A BIOMARKER OF IMMUNE SUPPRESSION AND A HIGHER RISK OF PROGRESSION.

EHA Library, Nicolas Chapuis, 420820

MYELODYSPLASTIC SYNDROMES BENEFIT OF IRON-RESTRICTED BONE MARROW TRANSPLANTATION IN PRECLINICAL STUDIES

EHA Library, Francesca Vinchi, 420821

PRIMARY U2AF1(S34F) MUTATED HEMATOPOIETIC CELLS ARE SENSITIVE TO NONSENSE-MEDIATED RNA DECAY DISRUPTION IN VIVO

EHA Library, Claudia Cabrera, 420822

DEVELOPMENT OF PATIENT DERIVED XENOGRAFT (PDX) MODELS OF MYELODYSPLASTIC SYNDROMES

EHA Library, Ângela Mesquita, 420823

ACTIVIN A INHIBITION BY ELRITERCEPT (KER-050) IS ASSOCIATED WITH EVIDENCE OF CARDIOVASCULAR BENEFIT: TRANSLATION OF PRECLINICAL OBSERVATIONS TO HUMANS WITH MDS

EHA Library, Shuhying Tan, 420824

TELOMERE BIOLOGY DRIVES AND SHAPES THE LANDSCAPE OF CLONAL MYELOID DISORDERS IN OLD AGE

EHA Library, Matthew McLoughlin, 420825

PATHOGENIC ROLES OF DDX41 MUTATIONS IN THE DEVELOPMENT OF MYELOID MALIGNANCIES

EHA Library, Ayana Kon, 420826

LUSPATERCEPT IMPROVES HEMATOPOIESIS IN LOWER-RISK MYELODYSPLASTIC SYNDROMES (MDS): COMPARATIVE BIOMARKER ANALYSIS OF RING SIDEROBLAST-POSITIVE AND -NEGATIVE SUBGROUPS FROM THE PHASE 3 COMMANDS STUDY

EHA Library, Uwe Platzbecker, 420827

UNRAVELING PATHOPHYSIOLOGY AND HEMATOPOIESIS OF VEXAS SYNDROME BY MULTI-OMICS ANALYSES AND TARGETED GENE EDITING

EHA Library, Samuele Ferrari, 420828

MOLECULAR AND CLINICAL CHARACTERIZATION OF ETNK1-MUTATED MYELOID NEOPLASMS: THE MAYO CLINIC EXPERIENCE AND FUTURE DIRECTIONS

EHA Library, Steven Tessier, 420829

EXPLORING SEX-DIVERSITY OF GENE MUTATIONS AND RESPONSE TO ESA TREATMENT IN LOW-RISK MYELODYSPLASTIC NEOPLASMS

EHA Library, Marco Raddi, 420830

IMPACT OF COMPLETE CYTOGENETIC RESPONSE IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES

EHA Library, Samuel Urrutia, 420831

REAL-WORLD DOSE ESCALATION AND OUTCOMES AMONG PATIENTS WITH LOWER-RISK MYELODYSPLASTIC SYNDROMES RECEIVING LUSPATERCEPT IN CLINICAL PRACTICE

EHA Library, Kashyap Patel, 420832

THE HUMANISTIC AND ECONOMIC BURDEN OF TRANSFUSION-DEPENDENT LOWER-RISK MYELODYSPLASTIC SYNDROMES ON PATIENTS IN NORTH AMERICA AND EUROPE

EHA Library, María Díez Campelo, 420833

ORAL DECITABINE/CEDAZURIDINE WITH VENETOCLAX VERSUS ORAL DECITABINE/CEDAZURIDINE IN HIGH-RISK MYELODYSPLASTIC SYNDROME: A PROPENSITY SCORE MATCHED ANALYSIS

EHA Library, Alex Bataller, 420834

ASSESSMENT OF CLINICAL OUTCOMES OF PATIENTS WITH MYELODYSPLASTIC SYNDROMES (MDS) WHO WERE TREATED WITH ORAL DECITABINE/CEDAZURIDINE (DEC-C) USING THE INTERNATIONAL WORKING GROUP (IWG) 2023 CRITERIA

EHA Library, Amer M. Zeidan, 420835

CLINICAL IMPLICATIONS OF SPLICING FACTOR MUTATIONS IN PATIENTS WITH HIGHER RISK MYELODYSPLASTIC SYNDROMES/NEOPLASMS TREATED WITH HYPOMETHYLATING AGENTS (HMA)- A MULTICENTER, RETROSPECTIVE ANALYSIS

EHA Library, Tariq Kewan, 420836

PHASE 1B STUDY OF SL-172154, A BI-FUNCTIONAL FUSION PROTEIN TARGETING CD47 AND CD40, WITH AZACITIDINE IN PREVIOUSLY UNTREATED ACUTE MYELOID LEUKEMIA AND HIGHER-RISK MYELODYSPLASTIC SYNDROMES

EHA Library, Amer Zeidan, 420837

RELATIONSHIP BETWEEN HAEMOGLOBIN AND QUALITY OF LIFE IN TRANSFUSION-DEPENDENT PATIENTS WITH LOWER-RISK MYELODYSPLASTIC SYNDROME RECEIVING LUSPATERCEPT OR EPOETIN ALFA

EHA Library, Esther Oliva, 420838

CLINICAL IMPLICATIONS OF IDH MUTATIONS (IDH MT) IN PATIENTS (PTS) WITH HIGHER-RISK MYELODYSPLASTIC SYNDROMES/NEOPLASMS (MDS) TREATED WITH HYPOMETHYLATING AGENTS (HMA)

EHA Library, Tariq Kewan, 420839

CPH DEEP NEURAL NETWORK DEMONSTRATES THAT IWG-2023-PROPOSED LOWERING OF HB THRESHOLD TO ≥10G/DL FOR RESPONSE ASSESSMENT DOES NOT RESULT IN WORSE OUTCOME PREDICTION THAN ≥11G/DL AS ASSESSED BY PB-CR

EHA Library, Lisa Pleyer, 420840

PREVALENCE AND CLINICAL SIGNIFICANCE OF GERMLINE VARIANTS IN CEBPA, DDX41, ETV6, GATA2 AND RUNX1 AMONG PATIENTS WITH MYELODYSPLASTIC SYNDROMES

EHA Library, Anna Tranberg, 420841

REAL-LIFE ANEMIA TREATMENT   IN LOW-RISK MYELODYSPLATIC SYNDROME (MDS) PATIENTS: A RETROSPECTIVE MULTICENTER STUDY BY THE GROUPE FRANCOPHONE DES MYÉLODYSPLASIES (GFM) ON 194 PATIENTS

EHA Library, abdessamia gandoul, 420842

MULTILINEAGE AND SAFETY RESULTS FROM THE COMMANDS TRIAL IN TRANSFUSION-DEPENDENT, ERYTHROPOIESIS-STIMULATING AGENT-NAIVE PATIENTS WITH VERY LOW-, LOW-, OR INTERMEDIATE-RISK MYELODYSPLASTIC SYNDROMES

EHA Library, Guillermo Garcia-Manero, 420844

PERIPHERAL BLOOD COMPLETE REMISSION (PB-CR) IS ASSOCIATED WITH SIMILAR SURVIVAL AS CR PER IWG 2023 CRITERIA IN PATIENTS WITH HIGHER-RISK MDS – AN INTERNATIONAL STUDY FROM THE VALIDATE CONSORTIUM

EHA Library, Tariq Kewan, 420845

QUANTIFYING THE RELATIONSHIP BETWEEN TRANSFUSION INDEPENDENCE AND OVERALL SURVIVAL IN LOWER-RISK MYELODYSPLASTIC SYNDROMES

EHA Library, Luca Malcovati, 420846

SPECTRUM AND CLINICAL IMPLICATIONS OF EXTRAMEDULLARY MANIFESTATIONS IN CHRONIC MYELOMONOCYTIC LEUKEMIA

EHA Library, Guillermo Montalban-Bravo, 420847

CHARACTERISATION AND PROGNOSTIC IMPACT OF ZRSR2 MUTATIONS IN MYELOID NEOPLASMS

EHA Library, Aref Al-Kali, 420848

CLINICAL BENEFIT OF LUSPATERCEPT IN TRANSFUSION-DEPENDENT, ERYTHROPOIESIS-STIMULATING AGENT-NAIVE PATIENTS WITH VERY LOW-, LOW- OR INTERMEDIATE-RISK MYELODYSPLASTIC SYNDROMES IN THE COMMANDS TRIAL

EHA Library, Valeria SANTINI, 420849

VALIDATION OF IWG-2023 RESPONSE CRITERIA, EXPANSION TO INCLUDE ALL MDS/CMML/AML PATIENTS TREATED WITH AZACITIDINE, AND COMPARISON WITH IWG-2006 AND ELN-2022 CRITERIA USING A CPH DEEP NEURAL NETWORK

EHA Library, Lisa Pleyer, 420850

PROGNOSTIC FACTORS IN UNTREATED PATIENTS WITH MYELODYSPLASTIC SYNDROMES WITH ISOLATED 5Q DELETION

EHA Library, Maria Julia Montoro, 420851

PHASE I/II STUDY OF SECLIDEMSTAT, AN LSD1 INHIBITOR, IN COMBINATION WITH AZACITIDINE FOR PATIENTS WITH MYELODYSPLASTIC SYNDROMES AND CHRONIC MYELOMONOCYTIC LEUKEMIA

EHA Library, Guillermo Montalban-Bravo, 420852

VALUE OF EARLY LUSPATERCEPT USE IN LOWER-RISK MYELODYSPLASTIC SYNDROMES (LR-MDS)

EHA Library, David Valcárcel, 420853

RED BLOOD CELL TRANSFUSION DEPENDENCY BURDEN IN LOWER-RISK MYELODYSPLASTIC SYNDROME PATIENTS IN FRANCE - EDELWEISS STUDY

EHA Library, Thibault Comont, 420854

CLINICAL SIGNIFICANCE OF GENOMIC LANDSCAPE IN PEDIATRIC ADVANCED MDS

EHA Library, chenmeng Liu, 420855

TARGETING LILRB4 (ILT3) USING IO-202 IN PATIENTS WITH CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML): INTERIM EFFICACY, SAFETY, AND MECHANISM OF ACTION DATA FROM THE PHASE 1B EXPANSION COHORT

EHA Library, Ahmed Aribi, 420856

RECLASSIFICATION MDS PATIENTS AND FURTHER EVALUATION THE IMPACT OF BONE MARROW FIBROSIS ACCORDING TO 5TH (2022) EDITIONS OF THE WHO CLASSIFICATION OF MYELODYSPLASTIC NEOPLASMS

EHA Library, Gaixiang Xu, 420857

RISK STRATIFICATION IN HYPOMETHYLATING AGENT-TREATED PATIENTS WITH MYELODYSPLASTIC SYNDROMES: A MULTIVARIATE MODEL

EHA Library, Kelly Chien, 420858

THE DYNAMIC CHANGES OF GENETIC MUTATIONS DURING THE DISEASE COURSE OF MYELODYSPLASTIC NEOPLASMS

EHA Library, Zheng Ge, 420859

VALIDATION AND COMPARISON OF 5TH EDITION WHO CLASSIFICATION (WHO 2022) AND INTERNATIONAL CONSENSUS CLASSIFICATION (ICC) PROPOSALS FOR MDS-SFB31

EHA Library, Linlin Liu, 420860

MYELODYSPLASTIC SYNDROMES WITH CONCOMITANT SF3B1 MUTATION AND DELETION OF THE LONG ARM OF CHROMOSOME 5

EHA Library, Zaker Schwabkey, 420861

ES-3000, A WNT/ Β CATENIN/INFLAMMASOME PATHWAY INHIBITOR COMBINED WITH ORAL DECITABINE/CEDAZURIDINE(ASTX727) FOR PATIENTS WITH MYELODYSPLASIA

EHA Library, Anoop Enjeti, 420862

QUESTIONABLE BENEFIT OF PRIOR THERAPY IN MDS PATIENTS UNDERGOING ALLOGENEIC STEM CELL TRANSPLANTATION: A RETROSPECTIVE ANALYSIS OF THE EBMT CHRONIC MALIGNANCIES WORKING PARTY

EHA Library, Christoph Scheid, 420863

A PHASE I STUDY OF ANTI-TIM-3 ANTIBODY TQB2618 ADDED TO HYPOMETHYLATING AGENTS (HMAS) IN ADULT PATIENTS WITH HIGHER-RISK MYELODYSPLASTIC SYNDROMES (MDS)

EHA Library, Yu Wu, 420864

AN IMMUNE DYSFUNCTION SIGNATURE ROBUSTLY ILLUMINATES DISEASE DYNAMICS AND PREDICTS SURVIVAL IN MDS/CMML PATIENTS: INSIGHTS FROM A LONGITUDINAL, MULTICENTER STUDY

EHA Library, Yu-Hung Wang, 420865

THE IMPLICATION OF TP53 ALLELIC STATUS FOR OUTCOME AND ERYTHROPOIESIS IN MDS

EHA Library, Bing Li, 420866

MOLECULAR EVENTS CONTRIBUTING TO THE IMMUNE-MEDIATED BONE MARROW FAILURE IN IDIOPATHIC APLASTIC ANEMIA

EHA Library, Zuzana Lenertova, 420867

SPLICING ALTERATIONS CAUSED BY U2AF1MT-S34 MODIFY THE TRANSCRIPTOME OF POT1 IN PATIENTS WITH TELOMERE BIOLOGY DISORDERS

EHA Library, Alejandro Ferrer, 420868

ZMAT3 PREVENTS HEMATOPOIETIC STEM CELL EXHAUSTION AND CONTRIBUTES TO CELL TRANSFORMATION BY MODULATING SPHINGOLIPID METABOLISM IN FANCONI ANEMIA DISEASE.

EHA Library, Maeva Loock, 420869

METABOLOMICS AND OXIDATIVE DAMAGE IN DIAMOND-BLACKFAN ANEMIA

EHA Library, Ondrej Jahoda, 420870

LONG-READ HLA SEQUENCING UNCOVERS SPECIFIC RISK ALLELES AND CLINICAL ASSOCIATIONS IN APLASTIC ANEMIA

EHA Library, Sunisa Kongkiatkamon, 420871

SPECTRUM OF GENETIC VARIANTS IN AN ARGENTINE PEDIATRIC COHORT WITH SUSPECTED INHERITED BONE MARROW FAILURE SYNDROMES

EHA Library, Agustina Albero, 420872

MUC4 GENE MUTATION PROMOTE COMPLEMENT DEPOSITION AND INCREASE THE RISK OF THROMBOTIC EVENTS IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA

EHA Library, Rong Fu, 420873

EXPRESSION AND MECHANISM OF ACTION OF ASH1L IN NK CELL OF SEVERE APLASTIC ANAEMIA

EHA Library, Mengran Gao, 420874

GENETIC VARIANTS AND INBORN ERRORS OF IMMUNITY IN BONE MARROW FAILURE: NOVEL POTENTIAL DRUG TARGETS FOR PRECISION MEDICINE

EHA Library, Vanessa Desantis, 420875

EFFICACY AND SAFETY OF INTENSIVE PEGCETACOPLAN DOSING FOR THE TREATMENT OF ACUTE HEMOLYSIS IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA

EHA Library, Morag Griffin, 420876

A NOVEL AUTOSOMAL RECESSIVE TELOMERE BIOLOGY DISORDER CAUSED BY BIALLELIC VARIANTS IN POLA2

EHA Library, Bianca Tesi, 420877

LATE ONSET AND LONG LASTING NEUTROPENIA  IN CHILDREN AND CHRONIC IDIOPATHIC NEUTROPENIA IN ADULTS: DESCRIPTION OF CLINICAL/ IMMUNOLOGICAL PHENOTYPE AND PRELIMINARY WES RESULTS.

EHA Library, Francesca Fioredda, 420878

CLINICAL CHARACTERISTICS AND PROGNOSIS OF SHWACHMAN-DIAMOND SYNDROME PATIENTS WITH MYELODYSPLASTIC SYNDROME OR ACUTE MYELOID LEUKEMIA  IN CHINA

EHA Library, Yang Wan, 420879

LONG-TERM OUTCOMES OF PEGCETACOPLAN TREATMENT IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA AND BASELINE HEMOGLOBIN LEVELS GREATER THAN 10 GRAMS PER DECILITER

EHA Library, Jens Panse, 420880

OUTPATIENT SUBCUTANEOUS ALEMTUZUMAB IS FEASIBLE AND SAFE FOR APLASTIC ANEMIA AND ASSOCIATED WITH HIGH RESPONSE RATES.

EHA Library, Celso Arrais-Rodrigues, 420881

MUTATIONAL LANDSCAPE IN PATIENTS WITH SEVERE APLASTIC ANEMIA IN TAIWAN AND THE CLINICAL SIGNIFICANCE

EHA Library, Kuojui Sun, 420882

CHARACTERIZATION OF CLINICALLY SIGNIFICANT BREAKTHROUGH HEMOLYSIS IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATED WITH PEGCETACOPLAN

EHA Library, Regis Peffault De La Tour, 420883